SENTI BIOSCIENCES INC (SNTI)
US81726A1007 - Common Stock
SNTI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. While SNTI seems to be doing ok healthwise, there are quite some concerns on its profitability. SNTI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SNTI had negative earnings in the past year.
In the past year SNTI has reported a negative cash flow from operations.
SNTI had negative earnings in each of the past 5 years.
In the past 5 years SNTI always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of SNTI (-65.53%) is worse than 62.61% of its industry peers.
SNTI has a Return On Equity of -129.00%. This is in the lower half of the industry: SNTI underperforms 60.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.53% | ||
| ROE | -129% | ||
| ROIC | N/A |
ROA(3y)-49.62%
ROA(5y)-49.82%
ROE(3y)-81.17%
ROE(5y)-85.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SNTI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNTI has less shares outstanding
Compared to 1 year ago, SNTI has a worse debt to assets ratio.
2.2 Solvency
SNTI has an Altman-Z score of -5.88. This is a bad value and indicates that SNTI is not financially healthy and even has some risk of bankruptcy.
SNTI's Altman-Z score of -5.88 is on the low side compared to the rest of the industry. SNTI is outperformed by 65.61% of its industry peers.
SNTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.88 |
ROIC/WACCN/A
WACC10.41%
2.3 Liquidity
A Current Ratio of 4.89 indicates that SNTI has no problem at all paying its short term obligations.
With a Current ratio value of 4.89, SNTI perfoms like the industry average, outperforming 53.26% of the companies in the same industry.
SNTI has a Quick Ratio of 4.89. This indicates that SNTI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.89, SNTI is in line with its industry, outperforming 54.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.89 | ||
| Quick Ratio | 4.89 |
3. Growth
3.1 Past
The earnings per share for SNTI have decreased strongly by -493.48% in the last year.
Looking at the last year, SNTI shows a very negative growth in Revenue. The Revenue has decreased by -91.63% in the last year.
SNTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.01% yearly.
EPS 1Y (TTM)-493.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-483.41%
Revenue 1Y (TTM)-91.63%
Revenue growth 3Y65.01%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
SNTI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.01% yearly.
Based on estimates for the next years, SNTI will show a very strong growth in Revenue. The Revenue will grow by 67.25% on average per year.
EPS Next Y50.76%
EPS Next 2Y36.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year286.96%
Revenue Next 2Y223.03%
Revenue Next 3Y18.22%
Revenue Next 5Y67.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNTI. In the last year negative earnings were reported.
Also next year SNTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNTI's earnings are expected to grow with 36.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.01%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SNTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENTI BIOSCIENCES INC
NASDAQ:SNTI (12/4/2024, 8:00:02 PM)
After market: 6.55 -0.06 (-0.91%)6.61
-0.53 (-7.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap30.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.53% | ||
| ROE | -129% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.89 | ||
| Quick Ratio | 4.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-493.48%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y50.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-91.63%
Revenue growth 3Y65.01%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y